Announcements
- Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
- Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
- Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.9984 |
---|---|
High | 0.9984 |
Low | 0.70 |
Bid | 0.77 |
Offer | 0.8299 |
Previous close | 0.7899 |
Average volume | 631.04k |
---|---|
Shares outstanding | 6.05m |
Free float | 4.77m |
P/E (TTM) | -- |
Market cap | 4.78m USD |
EPS (TTM) | -22.66 USD |
Data delayed at least 15 minutes, as of May 21 2024 20:59 BST.
More ▼